Humulin I (Isophane)

Humulin I (Isophane) is an insulin product whose active ingredient is insulin human (isophane). It is supplied as an injectable solution for subcutaneous administration. The formulation provides a protamine‑combined, intermediate‑acting insulin preparation; the specific strength is not listed in the available data. Humulin I is marketed in the European Union, belongs to the insulin drug class, and is used to help control blood glucose levels in diabetes.

Humulin I (Isophane) is indicated for the management of hyperglycemia in patients with diabetes mellitus. It is used as part of a comprehensive diabetes treatment plan that may include diet, exercise, and other glucose‑lowering agents.

- Type 1 diabetes mellitus requiring basal insulin coverage. - Type 2 diabetes mellitus when basal insulin is indicated. - Adjunct therapy in patients transitioning from short‑acting insulin regimens. - Use in combination with rapid‑acting insulin analogues for basal‑bolus therapy. - Situations where a steady, intermediate‑acting insulin profile is preferred.

Adverse reactions to Humulin I (Isophane) can vary in frequency and severity. Patients should be aware of both common and potentially serious events.

Common: - Hypoglycemia, especially if meals are delayed or doses are mismatched. - Injection site reactions such as redness, swelling, or itching. - Lipodystrophy, including lipoatrophy or lipohypertrophy at the injection site. - Weight gain associated with improved glycemic control. - Localized bruising or bleeding at the injection site. - Localized bruising or bleeding at the injection site.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions ranging from urticaria to anaphylaxis. - Edema or fluid retention, particularly in patients with cardiac or renal disease. - Rare cases of insulin antibody formation causing resistance. - Hypersensitivity reactions that may progress to serum sickness.

When prescribing or using Humulin I (Isophane), clinicians and patients should consider several precautionary measures to minimize risks and ensure optimal therapy.

- Assess renal and hepatic function before initiating therapy and monitor periodically. - Adjust doses in patients with fluctuating dietary intake or physical activity. - Use caution in pregnant or breastfeeding women; benefits must outweigh potential risks. - Avoid use in patients with known hypersensitivity to insulin or protamine. - Educate patients on proper injection technique to prevent lipodystrophy. - Monitor for signs of hypoglycemia, especially in the elderly or those on concomitant glucose‑lowering drugs. - Review concomitant medications that may mask hypoglycemia symptoms.

Humulin I (Isophane) may interact with other agents that affect blood glucose or insulin metabolism. Recognizing these interactions helps to avoid adverse events.

Avoid: - Concurrent use of other insulin products without dose adjustment. - Beta‑blockers that can mask hypoglycemia symptoms. - High‑dose corticosteroids that increase insulin resistance. - MAO inhibitors, which may alter insulin metabolism.

Use with caution: - Oral antidiabetic agents such as sulfonylureas or meglitinides, which may potentiate hypoglycemia. - ACE inhibitors or ARBs, which can enhance insulin sensitivity. - Thyroid hormones, as hyperthyroidism may increase insulin requirements. - Alcohol, especially in excess, which can cause unpredictable glucose fluctuations. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may affect renal function and insulin clearance.